Gilead Sciences, Inc. (GILD) Holdings Raised by Alpha Omega Wealth Management LLC
Alpha Omega Wealth Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% in the fourth quarter, Holdings Channel reports. The fund owned 45,264 shares of the biopharmaceutical company’s stock after purchasing an additional 2,897 shares during the period. Gilead Sciences makes up approximately 1.6% of Alpha Omega Wealth Management LLC’s investment portfolio, making the stock its 26th biggest position. Alpha Omega Wealth Management LLC’s holdings in Gilead Sciences were worth $3,243,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Welch Investments LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $108,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $133,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $147,000. Finally, Hanson & Doremus Investment Management increased its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the last quarter. Institutional investors and hedge funds own 77.83% of the company’s stock.
A number of brokerages have weighed in on GILD. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 price target for the company. in a research report on Monday, January 29th. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Bank of America lifted their price objective on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 7th. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $88.61.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company’s revenue was down 18.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.70 EPS. equities analysts forecast that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 65.52%.
In other news, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $80.93, for a total transaction of $472,064.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. Insiders have sold a total of 436,101 shares of company stock valued at $34,541,560 in the last 90 days. Insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.